Table 2 Patients baseline characteristics and ATO efficacy at week 24
Baseline | ATO dosage mg/kg/d | Week 24 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Patient no., gender, age (years) | SLE duration (years) | Previous IS | Concomitant treatment | Symptoms | SLEDAI | OCS mg/d | Severe flare | SLEDAI | OCS mg/d | W24 SRI-4-R | |
1. F, 35 | 12 | MTX | HCQ, THAL, MTX | A, C | 10 | 15 | 0.10 | W24 | 8 | 10 | No |
2. F, 41 | 23 | MTX | HCQ | A, C | 12 | 15 | 0.10 | No | 2 | 2.5 | Yes |
3. F, 49 | 29 | anti-Fcg-R mAb | HCQ | A, C | 10 | 15 | 0.10 | No | 4 | 7 | Yes |
4. M, 37 | 2 | MTX | HCQ, MTX | A, C | 6 | 10 | 0.10 | No | 2 | 8 | Yes |
5. F, 47 | 26 | CYC, Ci, MMF, RTX, THAL | HCQ | A | 8 | 15 | 0.15 | No | 10 | 15 | No |
6. F, 30 | 4 | BELI, MTX, EPRA, LEFLU, | HCQ | A, C | 6 | 10 | 0.15 | No | 6 | 7.5 | No |
7. F, 50 | 14 | MTX | HCQ | A | 8 | 12.5 | 0.15 | W20 | 20 | 2 | No |
8. H, 53 | 3 | MTX | HCQ, MTX | A, C | 8 | 10 | 0.20 | No | 0 | 5 | Yes |
9. F, 45 | 15 | MTX, AZA, CYC | MMF | A, C | 16 | 10 | 0.20 | No | 4 | 5 | Yes |
10. F, 23 | 6 | AZA | HCQ, AZA | A, C | 6 | 10 | 0.20 | No | 4 | 5 | No |